shine-logo

SHINE Announces Chris Vessell as General Manager of Therapeutics Division

JANESVILLE, Wis., May 23, 2022 – SHINE Technologies, LLC (SHINE), a next-generation nuclear technology company, today announced Chris Vessell has joined as General Manager of the Therapeutics Division. In this role, he will be responsible for developing and building the team dedicated to SHINE’s strategy and offerings around non-carrier-added lutetium-177 for cancer therapies.

2022-05-23T14:37:54-05:00May 23, 2022|2022, News, News Releases, Therapeutics|

SHINE Europe B.V. Designing Advanced Medical Isotopes Facility in the Netherlands

A leader in nuclear technology obtains funding to produce medical isotopes in Europe and to help meet growing demands to provide diagnostic imaging for life-threatening diseases on a global scale.

2022-02-01T17:57:14-06:00February 2, 2022|2022, News, News Releases|

SHINE & IOCB deliver Lu-177 doses to GE

SHINE Medical Technologies LLC, the Institute of Organic Chemistry and Biochemistry (IOCB Prague) and GE Healthcare today announced the production of patient doses of the therapeutic isotope lutetium-177 (Lu-177).

2021-12-16T20:07:30-06:00January 21, 2020|2020, Medical Isotopes, News, News Releases, Therapeutics|

Grand Opening of new SHINE Global HQ

January 16, 2017 - SHINE Medical Technologies, Inc. (SHINE), a company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, held a ribbon cutting ceremony to celebrate the grand opening of the company’s new global headquarters in downtown Janesville, Wisconsin. The ribbon cutting was led by the John Beckord and the Forward Janesville Goodwill Ambassadors.

2021-12-17T18:52:45-06:00January 16, 2017|2017, Archived, News, News Releases|

It Takes Two: GE Healthcare and SHINE Team Up

November 9, 2015 - Today, SHINE and GE Healthcare announced they have successfully obtained pharmaceutical-grade Tc‑99m from GE Healthcare’s DRYTEC™ Tc-99m (Kit for the Preparation of Sodium Pertechnetate Technetium Tc99m Injection), using Mo-99 produced by SHINE’s innovative process.

2021-12-17T18:55:31-06:00November 9, 2015|Archived, Medical Isotopes, News Releases|
Go to Top